Radiation Therapy (RT) For Parkinson’s Disease (PD)

Overview

About this study

The purpose of this study is to assess the efficacy of ultra-low dose radiation therapy to slow progression and symptoms of Parkinson’s Disease. Slowing of progression will be defined as a 7-point decrease in the MDS-UPDRS Part III (physician-assessed motor symptoms) score at 6 months post-RT.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥18 and ≤ 60 years.
  • Diagnosis of Parkinson’s disease by a Movement Disorder Neurologist
  • Confirmation of unilateral Parkinson’s disease by Dopamine Transporter (DaT) scan
  • A score of 2 or less on the modified Hoehn and Yahr scale
  • ECOG Performance Status (PS) ≤ 2.
  • No known genetic causes or predisposition to Parkinson’s disease or related diseases.
  • Ability to complete questionnaire(s), neurological exam, and follow-up imaging independently or with assistance
  • Provide written informed consent and co-enrolled in IRB# 18-002938
  • Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).

Exclusion Criteria:

  • Concomitant dementia diagnosis or concerns of other memory disorder
  • No Parkinson’s Disease medication changes within the last 3 months
  • Will not receive any radiation therapy elsewhere for Parkinson’s Disease outside Mayo Clinic Rochester

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 08/28/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Yasamin Sharifzadeh-Moghaddam

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20597064

Mayo Clinic Footer